Literature DB >> 27604949

Multifocality in Sporadic Medullary Thyroid Carcinoma: An International Multicenter Study.

Garth F Essig1, Kyle Porter2, David Schneider3, Debora Arpaia4, Susan C Lindsey5, Giulia Busonero6, Daniel Fineberg7, Barbara Fruci8, Kristien Boelaert9, Johannes W Smit10, Johannes Arnoldus Anthonius Meijer11, Leonidas H Duntas12, Neil Sharma13, Giuseppe Costante14, Sebastiano Filetti15, Rebecca S Sippel3, Bernadette Biondi4, Duncan J Topliss7, Furio Pacini6, Rui M B Maciel5, Patrick C Walz1, Richard T Kloos16.   

Abstract

BACKGROUND: Current surgical standard of care in sporadic medullary thyroid carcinoma (sMTC) consists of a minimum of total thyroidectomy with central neck dissection. Some have suggested thyroid lobectomy with isthmusectomy and central neck dissection for patients with sMTC, given their lower frequency of bilateral disease, although this topic has not been thoroughly studied. This study assessed the prevalence of multifocality in sMTC via a large international multi-institutional retrospective review to quantify this prevalence, including the impact of geography, to assess more accurately the risks associated with alternative surgical approaches.
METHODS: A retrospective chart review of sMTC patients from 11 institutions over 29 years (1983-2011) was undertaken. Data regarding focality, extent of disease, RET germline analysis plus family and clinical history for multiple endocrine neoplasia type 2 (MEN2), and demographic data were collected and analyzed.
RESULTS: Patients from four continents and seven countries were included in the sample. Data for 313 patients with documented sMTC were collected. Of these, 81.2% were confirmed with negative RET germline testing, while the remaining 18.8% demonstrated a negative family history and no manifestations of MEN2 syndromes other than MTC. Bilateral disease was identified in 17/306 (5.6%) patients, while multifocal disease was noted in 50/312 (16.0%) sMTC patients. When only accounting for germline negative patients, these rates were not significantly different (5.6% and 17%, respectively). Among them, when disease was unifocal in the ipsilateral lobe and isthmus, bilateral disease was present in 6/212 (2.8%) cases. When disease was multifocal in the ipsilateral lobe or isthmus, then bilateral disease was present in 8/37 (21.6%) cases (p < 0.001). No geographic differences in focality were identified.
CONCLUSIONS: The 5.6% prevalence of bilateral foci in sMTC suggests that total thyroidectomy should remain the standard of care for initial surgery, as less complete thyroid surgery may fail to address fully the primary site of disease. Whether ipsilateral tumor focality should be an independent factor determining the need for completion thyroidectomy when sMTC is diagnosed after hemithyroidectomy remains to be determined.

Entities:  

Keywords:  humans; medullary thyroid carcinoma; multifocality; surgery; thyroid neoplasm

Mesh:

Year:  2016        PMID: 27604949      PMCID: PMC6453487          DOI: 10.1089/thy.2016.0255

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  43 in total

1.  Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis.

Authors:  A Machens; O Gimm; J Ukkat; R Hinze; U Schneyer; H Dralle
Journal:  Cancer       Date:  2000-04-15       Impact factor: 6.860

2.  Medullary thyroid carcinoma in Northern Ireland, 1967-1997.

Authors:  S J Dolan; C F Russell
Journal:  Ann R Coll Surg Engl       Date:  2000-05       Impact factor: 1.891

3.  Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients.

Authors:  K Kaserer; C Scheuba; N Neuhold; A Weinhäusel; O A Haas; H Vierhapper; B Niederle
Journal:  Am J Surg Pathol       Date:  2001-10       Impact factor: 6.394

4.  Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas.

Authors:  T Weber; T Schilling; K Frank-Raue; M Colombo-Benkmann; U Hinz; R Ziegler; E Klar
Journal:  Surgery       Date:  2001-12       Impact factor: 3.982

5.  Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study.

Authors:  S A Hundahl; B Cady; M P Cunningham; E Mazzaferri; R F McKee; J Rosai; J P Shah; A M Fremgen; A K Stewart; S Hölzer
Journal:  Cancer       Date:  2000-07-01       Impact factor: 6.860

6.  Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations.

Authors:  Akira Miyauchi; Fumio Matsuzuka; Keisuke Hirai; Tamotsu Yokozawa; Kaoru Kobayashi; Yasuhiro Ito; Keiichi Nakano; Kanji Kuma; Hitoyasu Futami; Ken Yamaguchi
Journal:  World J Surg       Date:  2002-05-21       Impact factor: 3.352

7.  Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.

Authors:  E Kebebew; P H Ituarte; A E Siperstein; Q Y Duh; O H Clark
Journal:  Cancer       Date:  2000-03-01       Impact factor: 6.860

8.  Unilateral surgery supported by germline RET oncogene mutation analysis in patients with sporadic medullary thyroid carcinoma.

Authors:  A Miyauchi; F Matsuzuka; K Hirai; T Yokozawa; K Kobayashi; S Kuma; K Kuma; H Futami; K Yamaguchi
Journal:  World J Surg       Date:  2000-11       Impact factor: 3.352

9.  Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer.

Authors:  Claudia Scollo; Eric Baudin; Jean-Paul Travagli; Bernard Caillou; Nicolas Bellon; Sophie Leboulleux; Martin Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2003-05       Impact factor: 5.958

10.  C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients.

Authors:  Serge Guyétant; Nicolas Josselin; Fréderique Savagner; Vincent Rohmer; Sophie Michalak; Jean-Paul Saint-André
Journal:  Mod Pathol       Date:  2003-08       Impact factor: 7.842

View more
  5 in total

Review 1.  Nodular Thyroid Disease and Thyroid Cancer in the Era of Precision Medicine.

Authors:  Carles Zafon; Juan J Díez; Juan C Galofré; David S Cooper
Journal:  Eur Thyroid J       Date:  2017-03-03

2.  Surgical selection and prognostic analysis in patients with unilateral sporadic medullary thyroid carcinoma.

Authors:  Jinming Zhang; Pengfei Gu; Dongmei Huang; Jingzhu Zhao; Xiangqian Zheng; Ming Gao
Journal:  Langenbecks Arch Surg       Date:  2022-06-24       Impact factor: 3.445

3.  Prognostic value of LODDS in medullary thyroid carcinoma based on competing risk model and propensity score matching analysis.

Authors:  Zhe Xu Cao; Xin Weng; Jiang Sheng Huang; Xia Long
Journal:  Updates Surg       Date:  2022-07-12

4.  Risk Factors Associated With Reoperation and Disease-Specific Mortality in Patients With Medullary Thyroid Carcinoma.

Authors:  Eric J Kuo; Shonan Sho; Ning Li; Kyle A Zanocco; Michael W Yeh; Masha J Livhits
Journal:  JAMA Surg       Date:  2018-01-01       Impact factor: 14.766

Review 5.  Management of medullary carcinoma of the thyroid: a review.

Authors:  Ravindri Jayasinghe; Oshan Basnayake; Umesh Jayarajah; Sanjeewa Seneviratne
Journal:  J Int Med Res       Date:  2022-07       Impact factor: 1.573

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.